1.
Product Overview
2.
Research Methodology
3.
Impact of COVID-19 on Global CAR-T Cell Therapy Market
4. Executive Summary
5.
Voice of Customer
6.
Global CAR-T Cell Therapy Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1. By Indication
(Diffused Large B-cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL),
Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma
(FL), Others)
6.2.2. By Targeted Antigen
(CD 19, CD22, BCMA (B-Cell Maturation Antigen), HER1, HER2, Meso, EGFRvlll,
Others)
6.2.3. By Product Type
(Yescarta (Axicabtagene Ciloleucel), Kymriah (Tisagenlecleucel), JCAR017
(Lisocabtagene Maraleucel), bb2121)
6.2.4. By End User (Hospitals,
Cancer Treatment Centers, Others)
6.2.5. By Company (2019)
6.2.6. By
Region
6.3. Product
Market Map
7.
Asia-Pacific CAR-T Cell Therapy Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1. By Indication
7.2.2. By Targeted Antigen
7.2.3. By Product Type
7.2.4. By End User
7.2.5.
By Country
7.3.
Asia-Pacific: Country Analysis
7.3.1.
China CAR-T Cell Therapy Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Indication
7.3.1.2.2.
By Targeted Antigen
7.3.1.2.3.
By Product Type
7.3.1.2.4.
By End User
7.3.2.
India CAR-T Cell Therapy Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Indication
7.3.2.2.2.
By Targeted Antigen
7.3.2.2.3.
By Product Type
7.3.2.2.4.
By End User
7.3.3.
Japan CAR-T Cell Therapy Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Indication
7.3.3.2.2.
By Targeted Antigen
7.3.3.2.3.
By Product Type
7.3.3.2.4.
By End User
7.3.4.
South Korea CAR-T Cell Therapy Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Indication
7.3.4.2.2.
By Targeted Antigen
7.3.4.2.3.
By Product Type
7.3.4.2.4.
By End User
7.3.5.
Singapore CAR-T Cell Therapy Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Indication
7.3.5.2.2.
By Targeted Antigen
7.3.5.2.3.
By Product Type
7.3.5.2.4.
By End User
7.3.6.
Australia CAR-T Cell Therapy Market Outlook
7.3.6.1.
Market Size & Forecast
7.3.6.1.1.
By Value
7.3.6.2.
Market Share & Forecast
7.3.6.2.1.
By Indication
7.3.6.2.2.
By Targeted Antigen
7.3.6.2.3.
By Product Type
7.3.6.2.4.
By End User
8.
Europe CAR-T Cell Therapy Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1. By Indication
8.2.2. By Targeted Antigen
8.2.3. By Product Type
8.2.4. By End User
8.2.5.
By Country
8.3.
Europe: Country Analysis
8.3.1.
France CAR-T Cell Therapy Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Indication
8.3.1.2.2.
By Targeted Antigen
8.3.1.2.3.
By Product Type
8.3.1.2.4.
By End User
8.3.2.
Germany CAR-T Cell Therapy Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Indication
8.3.2.2.2.
By Targeted Antigen
8.3.2.2.3.
By Product Type
8.3.2.2.4.
By End User
8.3.3.
United Kingdom CAR-T Cell Therapy Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Indication
8.3.3.2.2.
By Targeted Antigen
8.3.3.2.3.
By Product Type
8.3.3.2.4.
By End User
8.3.4.
Italy CAR-T Cell Therapy Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Indication
8.3.4.2.2.
By Targeted Antigen
8.3.4.2.3.
By Product Type
8.3.4.2.4.
By End User
8.3.5.
Spain CAR-T Cell Therapy Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Indication
8.3.5.2.2.
By Targeted Antigen
8.3.5.2.3.
By Product Type
8.3.5.2.4.
By End User
9.
North America CAR-T Cell Therapy Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1. By Indication
9.2.2. By Targeted Antigen
9.2.3. By Product Type
9.2.4. By End User
9.2.5.
By Country
9.3.
North America: Country Analysis
9.3.1.
United States CAR-T Cell Therapy Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Indication
9.3.1.2.2.
By Targeted Antigen
9.3.1.2.3.
By Product Type
9.3.1.2.4.
By End User
9.3.2.
Mexico CAR-T Cell Therapy Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Indication
9.3.2.2.2.
By Targeted Antigen
9.3.2.2.3.
By Product Type
9.3.2.2.4.
By End User
9.3.3.
Canada CAR-T Cell Therapy Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Indication
9.3.3.2.2.
By Targeted Antigen
9.3.3.2.3.
By Product Type
9.3.3.2.4.
By End User
10.
South America CAR-T Cell Therapy Market Outlook
10.1.
Market Size & Forecast
10.1.1.
By Value
10.2.
Market Share & Forecast
10.2.1. By Indication
10.2.2. By Targeted Antigen
10.2.3. By Product Type
10.2.4. By End User
10.2.5.
By Country
10.3.
South America: Country Analysis
10.3.1.
Brazil CAR-T Cell Therapy Market Outlook
10.3.1.1.
Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2.
Market Share & Forecast
10.3.1.2.1.
By Indication
10.3.1.2.2.
By Targeted Antigen
10.3.1.2.3.
By Product Type
10.3.1.2.4.
By End User
10.3.2.
Argentina CAR-T Cell Therapy Market Outlook
10.3.2.1.
Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2.
Market Share & Forecast
10.3.2.2.1.
By Indication
10.3.2.2.2.
By Targeted Antigen
10.3.2.2.3.
By Product Type
10.3.2.2.4.
By End User
10.3.3.
Colombia CAR-T Cell Therapy Market Outlook
10.3.3.1.
Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2.
Market Share & Forecast
10.3.3.2.1.
By Indication
10.3.3.2.2.
By Targeted Antigen
10.3.3.2.3.
By Product Type
10.3.3.2.4.
By End User
11.
Middle East and Africa CAR-T Cell Therapy Market Outlook
11.1.
Market Size & Forecast
11.1.1.
By Value
11.2.
Market Share & Forecast
11.2.1. By Indication
11.2.2. By Targeted Antigen
11.2.3. By Product Type
11.2.4. By End User
11.2.5.
By Country
11.3.
MEA: Country Analysis
11.3.1.
South Africa CAR-T Cell Therapy Market Outlook
11.3.1.1.
Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2.
Market Share & Forecast
11.3.1.2.1.
By Indication
11.3.1.2.2.
By Targeted Antigen
11.3.1.2.3.
By Product Type
11.3.1.2.4.
By End User
11.3.2.
Saudi Arabia CAR-T Cell Therapy Market Outlook
11.3.2.1.
Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2.
Market Share & Forecast
11.3.2.2.1.
By Indication
11.3.2.2.2.
By Targeted Antigen
11.3.2.2.3.
By Product Type
11.3.2.2.4.
By End User
11.3.3.
UAE CAR-T Cell Therapy Market Outlook
11.3.3.1.
Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2.
Market Share & Forecast
11.3.3.2.1.
By Indication
11.3.3.2.2.
By Targeted Antigen
11.3.3.2.3.
By Product Type
11.3.3.2.4.
By End User
12.
Market Dynamics
12.1.
Drivers
12.2.
Challenges
13.
Market Trends & Developments
14.
Competitive Landscape
14.1.
Competition Outlook
14.2.
Players Profiled (Leading Companies)
14.2.1.
Kite Pharma
(subsidiary of Gilead Sciences)
14.2.2.
AbbVie Inc.
14.2.3.
Bluebird Bio
14.2.4.
Bristol Myers Squibb
(BMS)
14.2.5.
Gilead Sciences,
Inc.
14.2.6.
Cellectis
14.2.7.
Servier Laboratories
14.2.8.
Pfizer Inc.
14.2.9.
Merck KGaA
14.2.10.
Juno Therapeutics
14.2.11.
Amgen Inc.
14.2.12.
Intellia
Therapeutics
14.2.13.
Novartis
International AG
14.2.14.
Caribou Biosciences,
Inc.
14.2.15.
Celyad
14.2.16.
Bellicum
Pharmaceuticals, Inc.
14.2.17.
Noile-Immune Biotech
14.2.18.
Cartesian
Therapeutics
14.2.19.
Johnson &
Johnson
14.2.20.
Sangamo
Therapeutics, Inc.
15. Strategic Recommendations
16. About Us & Disclaimer
In case you don’t find what you are looking for, please get in touch with our custom research team at sales@techsciresearch.com